Amneal Pharmaceuticals

AMRX · NYSE

Share price · AMRX

$21.88+3.69 (+20.29%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.0M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AMRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 21 Sep 2026+7.7%
  2. 16 Sep 2026+8.6%
  3. 14 Aug 2026+5.1%
  4. 16 Jul 2026+4.9%
  5. 10 Jun 2026+4.3%

    Nothing announced by AMRX that day or the session before.

  6. 9 Jun 2026+7.1%
  7. 8 May 2026-3.8%
  8. 20 Apr 2026-4.7%
  9. 17 Apr 2026+6.3%
  10. 17 Mar 2026+4.1%

Share of unusual movement by asset

For each asset, the share of AMRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Crexont (IPX203) (Crexont)
events and moves
3shown from 8 days
Rytary (IPX066) (Rytary)
events and moves
1shown from 8 days
Dihydroergotamine mesylate (Brekiya) (Brekiya)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—73%

Assets

(6 total)
6Total Assets
6Approved
0Phase 3 / Filed
0Phase 1–2 / Early
7Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Approved
5-HT1D receptorSmall molecule
Migraine
Opicapone(Ongentys)
Approved
COMTSmall molecule
Parkinson's Disease
Approved
dopamine precursorSmall molecule
Parkinson's Disease
Approved
5-HT1B/1D receptorsSmall molecule
Migraine

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$863M$68M$180M$22M$98M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$796M$39M$140M—-$21M operating cash flowreport ↗
2026-Q1$723M$38M$204M—-$27M operating cash flowreport ↗
2025-Q3$785M$63M$238M—$118M operating cash flowreport ↗
2025-Q2$725M$48M$84M—$84M operating cash flowreport ↗
2025-Q1$695M$40M$68M—$7.4M operating cash flowreport ↗
2024-Q3$702M$61M$78M$0.2M$142M operating cash flowreport ↗
2024-Q2$702M$36M$50M—$40M operating cash flowreport ↗
2024-Q1$659M$39M$52M$92M-$4.4M operating cash flowreport ↗
2023-Q3$620M$41M$96M—$81M operating cash flowreport ↗
2023-Q2$599M$38M$115M—-$11M operating cash flowreport ↗
2023-Q1$558M$39M$151M$16M$140M operating cash flowreport ↗
2022-Q3$546M$50M$96M$7.6M$94M operating cash flowreport ↗
2022-Q2$559M$51M$98M$242M-$126M operating cash flowreport ↗
2022-Q1$498M$53M$217M$8.8M$120M operating cash flowreport ↗
2021-Q3$529M$49M$311M$7.8M$82M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.0B$186M$313M—$340M operating cash flowreport ↗

Amneal reported full-year 2025 revenue of $3,018.76M, up 8.0% YoY, with R&D spend of $186.18M, down 2.4% YoY, and cash and equivalents of $312.94M. Net income attributable to the company was $72.06M, with GAAP diluted EPS of $0.22.

Management provided 2026 guidance for net revenue of $3.05–$3.15B, Adjusted EBITDA of $720–$760M, and Adjusted diluted EPS of $0.93–$1.03. The company highlighted continued CREXONT uptake, the BREKIYA autoinjector launch, its first two inhalation products, and its fourth and fifth biosimilars.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$2.8B$191M$118M$29M$295M operating cash flowreport ↗
2023-FY$2.4B$164M$99M$20M$346M operating cash flowreport ↗
2022-FY$2.2B$196M$35M$68M$65M operating cash flowreport ↗
2021-FY$2.1B$202M$257M—$242M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 5 sales ($7.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-17BUCHI J KEVIN · directorGift20,445——Form 4
2026-09-11BUCHI J KEVIN · directorOption exercise20,445$14.45$295KForm 4
2026-09-11BUCHI J KEVIN · directorOption exercise (derivative)20,445——Form 4
2026-09-01BOYER ANDREW S · Executive Vice PresidentGift80,000——Form 4
2026-08-21BOYER ANDREW S · Executive Vice PresidentGift152,426——Form 4
2026-08-13Kiely John · directorOpen-market sale50,000$17.64$882KForm 4
2026-08-13Kiely John · directorGift10,000——Form 4
2026-08-12Shah Nikita · Executive Vice PresidentOpen-market sale146,403$17.51$2.6MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 314 reporting institutions held 159.8M shares ($1.9B).

#InstitutionSharesValue
1BlackRock, Inc.24,519,192$304.8M
2TPG GP A, LLC12,328,767$153.2M
3VANGUARD PORTFOLIO MANAGEMENT LLC11,324,933$140.8M
4Rubric Capital Management LP11,037,589$137.2M
5VANGUARD CAPITAL MANAGEMENT LLC7,585,034$94.3M
6STATE STREET CORP6,794,702$84.5M
7DIMENSIONAL FUND ADVISORS LP5,690,586$70.7M
8MORGAN STANLEY4,637,185$57.6M
9GEODE CAPITAL MANAGEMENT, LLC4,546,048$56.5M
10NEUBERGER BERMAN GROUP LLC3,682,284$45.7M
11Nuveen, LLC3,243,643$40.3M
12Invesco Ltd.3,188,659$39.6M
13Assenagon Asset Management S.A.3,067,361$38.1M
14GOLDMAN SACHS GROUP INC2,863,860$35.6M
15Nantahala Capital Management, LLC2,844,108$35.4M